AbbVie Inc. $ABBV Shares Sold by Homestead Advisers Corp

Homestead Advisers Corp cut its holdings in AbbVie Inc. (NYSE:ABBV) by 8.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 656,260 shares of the company’s stock after selling 57,600 shares during the quarter. AbbVie accounts for 3.6% of Homestead Advisers Corp’s portfolio, making the stock its 2nd biggest holding. Homestead Advisers Corp’s holdings in AbbVie were worth $151,950,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of ABBV. Brighton Jones LLC lifted its stake in shares of AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after purchasing an additional 3,401 shares during the period. Revolve Wealth Partners LLC increased its holdings in AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after buying an additional 3,064 shares in the last quarter. Joel Isaacson & Co. LLC lifted its position in shares of AbbVie by 1.2% during the 2nd quarter. Joel Isaacson & Co. LLC now owns 6,773 shares of the company’s stock valued at $1,257,000 after acquiring an additional 79 shares during the period. BankPlus Trust Department boosted its stake in shares of AbbVie by 3.3% during the 2nd quarter. BankPlus Trust Department now owns 27,113 shares of the company’s stock worth $5,033,000 after acquiring an additional 855 shares in the last quarter. Finally, Friedenthal Financial grew its holdings in shares of AbbVie by 3,152.5% in the 2nd quarter. Friedenthal Financial now owns 1,301 shares of the company’s stock worth $241,000 after acquiring an additional 1,261 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

ABBV has been the subject of several research reports. Berenberg Bank set a $275.00 price objective on AbbVie in a report on Tuesday, January 20th. HSBC raised AbbVie from a “hold” rating to a “buy” rating and lifted their price target for the stock from $225.00 to $265.00 in a research note on Wednesday, December 10th. DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective on the stock. in a research note on Tuesday, November 4th. Citigroup cut their target price on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research report on Tuesday, January 27th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $289.00 price target (up previously from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $251.50.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q4 beat and raised FY outlook — AbbVie reported Q4 adjusted EPS of $2.71 and revenue of $16.62B, topping estimates; management gave 2026 adjusted EPS guidance of $14.37–$14.57, above consensus, supporting the view of durable profit growth. Article Title
• Positive Sentiment: Immunology momentum — Strong demand for Skyrizi (+32% Y/Y) and Rinvoq (+29% Y/Y) drove the beat and are cited by management as the engine of revenue growth, partially offsetting Humira declines. Analysts point to continued upside from these franchises. Article Title
• Positive Sentiment: Rinvoq label expansion in progress — AbbVie submitted regulatory applications for Rinvoq (upadacitinib) in vitiligo (FDA/EMA), a meaningful new indication if approved that could support longer‑term growth. Article Title
• Neutral Sentiment: Analyst positioning mixed — Some firms (e.g., Evercore) kept bullish ratings citing immunology strength and neurology upside, while others are pausing to re‑assess targets; this is keeping trading volatile. Article Title
• Negative Sentiment: Q1 guidance missed expectations — AbbVie issued Q1 2026 EPS guidance of $2.97–$3.01 versus a ~ $3.11 consensus, and revenue guidance came in below forecasts, prompting concern about near‑term growth momentum. (Company guidance update)
• Negative Sentiment: Segment weakness and diversification worries — Aesthetics (Botox/Cosmetics) and parts of oncology showed declines and some reports flag that growth is concentrated in immunology; commentators warn the company may lean on M&A/IPR&D to sustain growth. Article Title
• Negative Sentiment: Investor skepticism on Rinvoq contribution and valuation questions — Some coverage highlights that Rinvoq’s role vs. expectations (and valuation implications for the company) remains under scrutiny despite the drug’s growth. Article Title

AbbVie Price Performance

AbbVie stock opened at $217.04 on Thursday. The stock has a market capitalization of $383.59 billion, a P/E ratio of 164.42, a P/E/G ratio of 0.93 and a beta of 0.35. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The firm’s 50-day moving average is $223.99 and its two-hundred day moving average is $219.14.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the prior year, the firm posted $2.16 earnings per share. The company’s quarterly revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.